Reactive oxygen species mediate soft corals-derived sinuleptolide-induced antiproliferation and DNA damage in oral cancer cells

Abstract: We previously reported that the soft coral-derived bioactive substance, sinuleptolide, can inhibit the proliferation of oral cancer cells in association with oxidative stress. The functional role of oxidative stress in the cell-killing effect of sinuleptolide on oral cancer cells was not investigated as yet. To address this question, we introduced the reactive oxygen species (ROS) scavenger (N-acetylcysteine [NAC]) in a pretreatment to evaluate the sinuleptolide-induced changes to cell viability, morphology, intracellular ROS, mitochondrial superoxide, apoptosis, and DNA damage of oral cancer cells (Ca9-22). After sinuleptolide treatment, antiproliferation, apoptosis-like morphology, ROS/mitochondrial superoxide generation, annexin V-based apoptosis, and γH2AX-based DNA damage were induced. All these changes were blocked by NAC pretreatment at 4 mM for 1 h. This showed that the cell-killing mechanism of oral cancer cells of sinuleptolide is ROS dependent.

Keywords: soft corals, oral cancer, N-acetylcysteine, oxidative stress, γH2AX

Introduction

Oral cancer is the sixth most prevalent form of cancer worldwide.1–2 Treatment options for oral cancer include surgery and chemotherapy. Several clinically approved drugs such as cisplatin are getting ineffective due to drug resistance in oral cancer therapy.3 Therefore, the discovery of new anti-oral cancer drugs becomes a challenging task.

Marine microbes, flora, and fauna provide promising sources of bioactive natural products, and they are used to develop well-received anticancer drugs.4–6 For example, peptides and roe protein hydrolysates derived from marine fish have been reported to inhibit the proliferation of oral cancer cells.7 The methanolic extract of red alga Gracilaria tenuistipitata was found to inhibit oral cancer cell proliferation.8 Limuacin, a marine microbial extract, was reported to induce autophagy and cell death in head and neck cancer cells.9 Accordingly, marine resources feature abundant natural marine products with potential anticancer effects.

Recently, many soft coral-derived compounds have been reported as having potential applications as anticancer drugs.10–12 Studies have investigated Sinularia lochmodes-derived sinuleptolide for marine natural product identification12 and for use in treating inflammation13 and skin cancer.14 The structure of sinuleptolide was first derived from the soft coral Simuliria sp.15 Alternatively, sinuleptolide was extracted from the soft corals Simuliria leptoclados and S. lochmodes in our laboratory.16,17 However, few studies have investigated the effects of sinuleptolide in the treatment of oral cancer.
In our recent study, we reported that oxidative stress was associated with the sinuleptolide-induced killing of oral cancer cells. However, the dependence of oxidative stress in the cell-killing effect of sinuleptolide on oral cancer cells was not investigated. N-acetylcysteine (NAC), a glutathione precursor for replenishing cellular glutathione storage, is a well-known reactive oxygen species (ROS) scavenger. NAC pretreatment can be used to investigate the role of oxidative stress dependence in drug and natural product-mediated cancer cell death. Therefore, the purpose of this study is to evaluate the role of oxidative stress in the cell-killing effects of sinuleptolide against oral cancer cells.

Materials and methods

Cell cultures and chemicals

Human oral cancer cells (Ca9-22), purchased from the Health Science Research Resources Bank (HSRRB) (Osaka, Japan), were incubated with DMEM medium (Gibco, Grand Island, NY, USA) and fetal bovine serum. Human normal gingival fibroblast cells (HGF-1), purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA), were incubated with DMEM-F12 medium (Gibco, Grand Island, NY, USA). These cells were maintained at 37°C in a humidified 5% CO2 atmosphere. The structure and preparation of soft corals Sinularia-derived sinuleptolide was isolated from S. lochmodes as described in our previous study. It was freshly prepared in dimethyl sulfoxide (DMSO) for cell studies. All the DMSO concentrations of sinuleptolide treatments were unified at 0.24%. NAC (Sigma, St Louis, MO, USA) was pretreated with 4 mM for 1 h before sinuleptolide treatment.

Cell viability

CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) (Promega Corporation, Madison, WI, USA) was chosen to measure cell proliferation. After plating overnight, Ca9-22 cells were incubated with sinuleptolide for 24 h with or without NAC pretreatment. Finally, the MTS response was measured by an ELISA reader (EZ Read 400 Research Reader; BioChrom, Cambridge, UK).

Intracellular ROS production

Intracellular hydrogen peroxide or other oxidizing ROS can react with 2,7'-dichlorodihydrofluorescein diacetate (DCFH-DA) and generate fluorescence. The ROS level can be detected using flow cytometry. In brief, after plating overnight, Ca9-22 cells were incubated with sinuleptolide for 3 h with or without NAC pretreatment. After washing with PBS, cells were incubated with 100 nM DCFH-DA in PBS at 37°C for 30 min. After harvesting, cells were resuspended in 1 mL PBS for flow cytometry analysis (BD Accuri™ C6; Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Mean intensity of ROS was collected from 1×10^4 cell counts.

Mitochondrial superoxide production

The mitochondrial superoxide was reacted with MitoSOX™ Red (Molecular Probes; Invitrogen, Eugene, OR, USA) and generated fluorescence. MitoSOX Red was also applied to flow cytometry. In brief, after plating overnight, Ca9-22 cells were incubated with sinuleptolide for 1 h with or without NAC pretreatment. Subsequently, cells were incubated with 5 µM MitoSOX 37°C for 30 min. After harvesting, cells were resuspended in 1 mL PBS for flow cytometer analysis (BD Accuri C6). Mean intensity of mitochondrial superoxide was collected from 1×10^4 cell counts.

DNA damage by γH2AX/propiodum iodide

γH2AX is the marker of DNA double-strand breaks, and it can be detected by flow cytometry. In brief, sinuleptolide-treated cells were fixed in 70% ethanol. After washing with BSA-T-PBS solution (1% bovine serum albumin and 0.2% Triton X-100 in PBS; Sigma), cells were incubated with p-Histone H2A.X (Ser 139) monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and BSA-T-PBS buffer in 1:50 dilution at 4°C for 1 h. After washing, Alexa Fluor 488-tagged secondary antibody (Jackson Laboratory, Bar Harbor, ME, USA) with BSA-T-PBS buffer in a 1:50 dilution was added for 30 min at room temperature. After the addition of 20 µg/mL of propidium iodide (PI), cells were resuspended for flow cytometry analysis (BD Accuri C6). Mean intensity of γH2AX was collected from 1×10^4 cell counts.

Statistical analysis

Experimental data were analyzed and expressed as mean ± SD. Data were analyzed using two-sample Student’s t-test with Bonferroni correction. The P-values <0.01 (=0.05/5) are considered as statistically significant.

Results

NAC effect on sinuleptolide-induced cell killing

In the MTS assay (Figure 1A and B), sinuleptolide concentration responsively decreased the cell viability (%) of
oral cancer cells (Ca9-22) and oral normal cells (HGF-1), but sinuleptolide selectively killed Ca9-22 cells and was less harmful to HGF-1 cells, which was consistent with our previous study. The IC50 values of sinuleptolide in Ca9-22 and HGF-1 cells were 11.76 and 22.3 µg/mL, respectively. As NAC is a common ROS scavenger, this NAC effect was used in the present study to address the dependence of oxidative stress for the sinuleptolide effect on oral cancer compared with normal cells. We found that the sinuleptolide (3–24 µg/mL)-induced cell killing in Ca9-22 and HGF-1 cells was significantly reduced by a pretreatment with NAC (P<0.002) (Figure 1A and B).

**NAC effect on sinuleptolide-induced morphology change**

The cell morphology was changed and became more abnormal in sinuleptolide-treated oral cancer cells (Ca9-22) (Figure 2A) than in HGF-1 cells (Figure 2B). At higher concentrations of sinuleptolide (12 and 24 µg/mL), apoptosis-like morphological changes, such as apoptotic

---

**Figure 1** NAC effect on cell viabilities of sinuleptolide-treated oral cancer and normal cells.

*Notes:* (A) Cell viabilities of oral cancer cells. (B) Cell viabilities of oral normal cells. With or without 4 mM NAC pretreatment for 1 h, oral cancer cells (Ca9-22) or oral normal cells (HGF-1) were incubated with 3, 6, 12, and 24 µg/mL of sinuleptolide for 24 h. Cell viability was measured by the MTS assay. Data, mean ± SD (n=6). **P-value of <0.002 for the significance between data with or without NAC pretreatment.

*Abbreviation:* NAC, N-acetylcysteine.

**Figure 2** NAC effect on cell morphology of sinuleptolide-treated oral cancer and oral normal cells.

*Notes:* NAC pretreatment condition was 4 mM for 1 h. No NAC pretreatment was kept in culture medium for 1 h. Cells were incubated with 0, 3, 6, 12, and 24 µg/mL of sinuleptolide for 24 h. (A and B) Cell morphology of sinuleptolide-treated oral cancer cells (Ca9-22) and oral normal cells (HGF-1). Cell morphology was observed under 100× magnification (scale bar is 100 µm).

*Abbreviation:* NAC, N-acetylcysteine.
bodies and cell shrinkages, were observed in Ca9-22 cells. However, these sinuleptolide-induced apoptosis-like or abnormal morphologies were reduced by NAC pretreatment.

NAC effect on the sinuleptolide-induced ROS generation

Figure 3A and B shows the relative ROS intensity patterns of sinuleptolide-induced ROS generation of Ca9-22 and HGF-1 cells with or without NAC pretreatment. At higher concentrations of sinuleptolide (12 and 24 µg/mL) (Figure 3C), the ROS generation of Ca9-22 cells was upregulated, which was consistent with the results of our previous study. After NAC pretreatment, the sinuleptolide-induced ROS generation of Ca9-22 cells was significantly reduced by NAC pretreatment ($P<0.002$) (Figure 3C). In contrast, the ROS generation of HGF-1 cells was maintained at a basal level with or without NAC pretreatment (Figure 3D).

NAC effect on the generation of sinuleptolide-induced mitochondrial superoxide

Mitochondria-specific ROS staining dye (MitoSOX Red) was used to evaluate mitochondrial superoxide by flow cytometry. Figure 4A and B shows the relative mitochondrial superoxide intensity patterns of NAC pretreatment effects against sinuleptolide-treated oral cancer and normal cells. Higher concentrations of sinuleptolide (12 and 24 µg/mL) (Figure 4C and D) induced the mitochondrial superoxide generation of Ca9-22 and HGF-1 cells. NAC pretreatment significantly reduced the sinuleptolide-induced mitochondrial superoxide generation of Ca9-22 and HGF-1 cells ($P<0.002$).

NAC effect on sinuleptolide-induced $\gamma$H2AX/PI-based DNA damage

Figure 5A and B shows the relative $\gamma$H2AX intensity patterns of sinuleptolide-induced DNA damage in Ca9-22 and HGF-1 cells with or without NAC pretreatment. At higher concentrations of sinuleptolide (12 and 24 µg/mL) (Figure 5C and D), the $\gamma$H2AX intensity was increased, which was consistent with the results of our previous study. After NAC pretreatment, the sinuleptolide-induced $\gamma$H2AX intensity was significantly reduced by NAC pretreatment ($P<0.002$) (Figure 5C). In contrast, the $\gamma$H2AX intensity of HGF-1 cells was maintained at a basal level with or without NAC pretreatment (Figure 5D).

Figure 3A and B shows the relative ROS intensity patterns of sinuleptolide-induced ROS generation of Ca9-22 and HGF-1 cells with or without NAC pretreatment. At higher concentrations of sinuleptolide (12 and 24 µg/mL) (Figure 3C), the ROS generation of Ca9-22 cells was upregulated, which was consistent with the results of our previous study. After NAC pretreatment, the sinuleptolide-induced ROS generation of Ca9-22 cells was significantly reduced by NAC pretreatment ($P<0.002$) (Figure 3C). In contrast, the ROS generation of HGF-1 cells was maintained at a basal level with or without NAC pretreatment (Figure 3D).

Figure 3A and B shows the relative ROS intensity patterns of sinuleptolide-induced ROS generation of Ca9-22 and HGF-1 cells with or without NAC pretreatment. At higher concentrations of sinuleptolide (12 and 24 µg/mL) (Figure 3C), the ROS generation of Ca9-22 cells was upregulated, which was consistent with the results of our previous study. After NAC pretreatment, the sinuleptolide-induced ROS generation of Ca9-22 cells was significantly reduced by NAC pretreatment ($P<0.002$) (Figure 3C). In contrast, the ROS generation of HGF-1 cells was maintained at a basal level with or without NAC pretreatment (Figure 3D).

Figure 3A and B shows the relative ROS intensity patterns of sinuleptolide-induced ROS generation of Ca9-22 and HGF-1 cells with or without NAC pretreatment. At higher concentrations of sinuleptolide (12 and 24 µg/mL) (Figure 3C), the ROS generation of Ca9-22 cells was upregulated, which was consistent with the results of our previous study. After NAC pretreatment, the sinuleptolide-induced ROS generation of Ca9-22 cells was significantly reduced by NAC pretreatment ($P<0.002$) (Figure 3C). In contrast, the ROS generation of HGF-1 cells was maintained at a basal level with or without NAC pretreatment (Figure 3D).

Figure 3A and B shows the relative ROS intensity patterns of sinuleptolide-induced ROS generation of Ca9-22 and HGF-1 cells with or without NAC pretreatment. At higher concentrations of sinuleptolide (12 and 24 µg/mL) (Figure 3C), the ROS generation of Ca9-22 cells was upregulated, which was consistent with the results of our previous study. After NAC pretreatment, the sinuleptolide-induced ROS generation of Ca9-22 cells was significantly reduced by NAC pretreatment ($P<0.002$) (Figure 3C). In contrast, the ROS generation of HGF-1 cells was maintained at a basal level with or without NAC pretreatment (Figure 3D).

Figure 3A and B shows the relative ROS intensity patterns of sinuleptolide-induced ROS generation of Ca9-22 and HGF-1 cells with or without NAC pretreatment. At higher concentrations of sinuleptolide (12 and 24 µg/mL) (Figure 3C), the ROS generation of Ca9-22 cells was upregulated, which was consistent with the results of our previous study. After NAC pretreatment, the sinuleptolide-induced ROS generation of Ca9-22 cells was significantly reduced by NAC pretreatment ($P<0.002$) (Figure 3C). In contrast, the ROS generation of HGF-1 cells was maintained at a basal level with or without NAC pretreatment (Figure 3D).

Figure 3A and B shows the relative ROS intensity patterns of sinuleptolide-induced ROS generation of Ca9-22 and HGF-1 cells with or without NAC pretreatment. At higher concentrations of sinuleptolide (12 and 24 µg/mL) (Figure 3C), the ROS generation of Ca9-22 cells was upregulated, which was consistent with the results of our previous study. After NAC pretreatment, the sinuleptolide-induced ROS generation of Ca9-22 cells was significantly reduced by NAC pretreatment ($P<0.002$) (Figure 3C). In contrast, the ROS generation of HGF-1 cells was maintained at a basal level with or without NAC pretreatment (Figure 3D).

Figure 3A and B shows the relative ROS intensity patterns of sinuleptolide-induced ROS generation of Ca9-22 and HGF-1 cells with or without NAC pretreatment. At higher concentrations of sinuleptolide (12 and 24 µg/mL) (Figure 3C), the ROS generation of Ca9-22 cells was upregulated, which was consistent with the results of our previous study. After NAC pretreatment, the sinuleptolide-induced ROS generation of Ca9-22 cells was significantly reduced by NAC pretreatment ($P<0.002$) (Figure 3C). In contrast, the ROS generation of HGF-1 cells was maintained at a basal level with or without NAC pretreatment (Figure 3D).
HGF-1 cells with or without NAC pretreatment. The higher concentrations of sinuleptolide (12 and 24 µg/mL) (Figure 5C) dramatically induced the γH2AX expression of Ca9-22 cells, which was consistent with our previous study.18 After NAC pretreatment, the sinuleptolide-induced γH2AX expression in Ca9-22 cells was significantly reduced by NAC pretreatment (P<0.002). In contrast, sinuleptolide-induced γH2AX expression of HGF-1 cells was maintained at a basal level with or without NAC pretreatment (Figure 5D).

Discussion

We could show here that NAC pretreatment inhibited sinuleptolide-induced cell killing, apoptosis-like morphology, and apoptosis of oral cancer cells. This indicated the role of oxidative stress in the cytotoxicity provided by sinuleptolide for oral cancer cells. Moreover, oxidative stress is involved in early apoptosis31 and mitochondrial dysfunction.32–34 NAC can interact with ROS, such as hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid.35 Consistently, we also found that NAC pretreatment inhibited sinuleptolide-induced ROS and the generation of mitochondrial superoxide. However, NAC is known to show other properties as well. For example, NAC also has anti-inflammatory effects.36–38 Since our study lacks experiments to exclude this possibility, sinuleptolide-induced cytotoxicity of oral cancer cells may also include other than an “ROS-dependent” mechanism.

DCFH-DA is used to detect intracellular ROS such as hydrogen peroxide, but does not specifically detect mitochondrial ROS. In contrast, MitoSOX Red dye has been reported to selectively detect superoxide in the mitochondria of live cells rather than other ROS.39 The role of mitochondrial superoxide was first reported as being involved in sinuleptolide-induced cytotoxicity in the present study. However, sinuleptolide induces cell death in both kinds of cells with different IC50 values (Ca9-22=11.76 and HGF-1=22.3 µg/mL). The reason for some differences only observed with ROS and DNA damage...
in sinuleptolide-treated cells remains unclear as yet. One possibility is that mitochondrial and cytoplasmic ROS have diverse functions. For example, accumulating evidence suggests that mitochondrial ROS are important for normal cell functioning. Mitochondrial and cytoplasmic ROS may play opposing effects throughout the life cycle. For Caenorhabditis elegans, the increase of mitochondrial ROS increases the lifespan of this invertebrate, whereas the increase of cytoplasm ROS decreases its lifespan. However, the detailed function of mitochondrial and cytoplasmic ROS in sinuleptolide-induced cytotoxicity against cancer cells warrants further investigation.

p53 is reported to highly regulate redox homeostasis and to modulate several ROS-regulating genes. In contrast, ROS can modify p53 conformation to adjust the transcription of p53. In the current study, ROS was validated to play an important role in sinuleptolide-induced cell death of oral cancer cells. However, the role of p53 in sinuleptolide-treated cells was not investigated in the current study. Furthermore, the status of p53 in Ca9-22 cells is a mutant form, but it is wild-type (wt) in the HGF-1 cells. Cells with mutant or wt p53 may display different responses. For example, hyperthermia induced apoptosis in oral squamous cell carcinoma (OSCC) cells (wt p53) and decreased IL-12 expression, but it increased IL-12Rβ1 in OSCC (mutated p53). Accordingly, the role of p53 in sinuleptolide-induced antiproliferation and DNA damage effects of oral cancer cells warrants further investigation in the future.

Mitochondria are commonly assumed to have a tubular form in healthy cells, but donut or blob forms increased with mitochondrial superoxide, suggesting that mitochondrial shape may change at different conditions of mitochondrial ROS generation. The mitochondrial superoxide intensity increased upon oxidative stress with inhibitors of the mitochondrial complex I (rotenone) and mitochondrial complex II (antimycin). NAC pretreatment has been reported.
to reduce mitochondrial superoxide levels and mitochondrial donut or blob formations.46 This suggests further investigation of sinuleptolide-induced mitochondrial shape change.

Moreover, oxidative stress commonly induces DNA damage,47 but we found that sinuleptolide-induced DNA damage was reduced by NAC pretreatment, suggesting that oxidative stress plays an important role in the DNA damaging effect of sinuleptolide in oral cancer cells. In addition, the sinuleptolide-induced DNA damage effect may have led to apoptosis in our previous study.18 Our preliminary result also found that sinuleptolide-induced apoptosis may be reduced by NAC pretreatment as indicated by the cleaved Poly (ADP-ribose) polymerase (PARP) assay (data not shown).

Some oxidative stress modulating drugs have been reported to modulate the endoplasmic reticulum (ER) stress provided by oxidative stress.48,49 ROS has also been reported to induce autophagy when exposed to nonmarine drugs and marine drugs.50 Because sinuleptolide-induced killing of oral cancer cells was shown to depend on oxidative stress, the possible responses of ER stress and autophagy in sinuleptolide-treated oral cancer cells warrant further investigation. Moreover, NAC was reported to inactivate c-Jun N-terminal kinase, p38 mitogen-activated protein kinase, activating protein-1, and nuclear factor kappa B.51 These kinase-signaling proteins need to be further investigated in terms of the sinuleptolide mediation in the future.

**Conclusion**

In conclusion, we demonstrated that sinuleptolide induces cell killing, apoptosis, and DNA damage in oral cancer cells by allowing for relatively high cellular ROS levels. This effect was significantly reduced by NAC pretreatment that allows ROS scavengers to reduce the actual ROS content (Figure 6). This suggests that the marine bioactive compound sinuleptolide kills oral cancer cells by mediating oxidative stress.

**Acknowledgments**

This work was supported by funds of the Ministry of Science and Technology (MOST 104-2320-B-037-013-MY3, MOST 104-2320-B-110-001-MY2, and MOST 105-2314-B-037-036), the National Sun Yat-sen University–KMU Joint Research Project (#NSYSU-KMU 106-p001), the Kaohsiung Municipal Ta-Tung Hospital (KMUH105-5R61), and the Health and welfare surcharge of tobacco products, the Ministry of Health and Welfare, Taiwan, Republic of China (MOHW105-TDU-B-212-134007). The authors thank Dr Hans-Uwe Dahms for help with English editing.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


